Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-09-16
2011-11-22
Nolan, Jason M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S365000, C548S197000, C548S205000
Reexamination Certificate
active
08063080
ABSTRACT:
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides heterocyclic aryl sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.
REFERENCES:
patent: 6262078 (2001-07-01), Loughhead et al.
patent: 7615569 (2009-11-01), Fulp et al.
patent: 2004/0106613 (2004-06-01), McNaughton-Smith et al.
patent: WO 2005/013914 (2005-02-01), None
Ono et al. Pflugers Arch—Eur. J. Physiol. 1995, 429, 561-569.
El-Emary et al. Phosphorus, Sulfur and Silicon and the Related Elements 2002, 177(1), 195-210.
Chaplan, S.R. et al., “Quantitative Assessment of Tactile Allodynia in the Rat Paw,”J. Neurosci. Methods, 53:55-63 (1994).
Devor, et al., “Na+Channel Immunolocalization in Peripheral Mammalian Axons and Changes Following Nerve Injury and Neuroma Formation,”J. Neurosci., 13(5):1976-1992 (May 1993).
Kim et al., “An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat,”Pain, 50:355-363 (1992).
Legroux-Crespel, E. et al., “Traitement de L'érythermalgie Familiale Par L'association Liodocaïne-Mexilétine,”Ann. Dermatol. Venereal, 130:429-33 (2003).
Priest et al.,PNAS, 2007, 104(20), 8205-8206.
Srivatsa, U. et al., “Mechanisms of Antiarrhythmic Drug Actions and Their Clinical Relevance for Controlling Disorders of Cardiac Rhythm,”Curr. Cardiol. Rep., 4(5):401-410 (Sep. 4, 2002).
Toledo-Aral et al., “Identification of PN1, a Predominant Voltage-Dependent Sodium channel Expressed Principally in Peripheral Neurons,”Proc. Natl. Acad. Sci.USA, 94:1527-1532 (Feb. 1997).
Wood, J. et al., “Voltage-Gated Sodium Channels and Pain Pathways,”J. Neurobiol., 61(1):55-71 (Oct. 2004).
Relevant portion of Supplementary European Search Report, Appln. No. EP 06813386, dated Jul. 12, 2010.
Fulp Alan
Marron Brian
Suto Mark J.
Wang Xiaodong
Icagen Inc.
Morgan & Lewis & Bockius, LLP
Nolan Jason M
LandOfFree
Inhibitors of ion channels does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of ion channels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of ion channels will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288473